Chlamydia Trachomatis Clinical Trial
Official title:
A Phase I First in Human, Double-blind, Parallel, Randomised and Placebo Controlled Clinical Trial of the Safety of SSI's Adjuvanted Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years
Verified date | August 2017 |
Source | Statens Serum Institut |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present trial is a phase I first in human, double blind, parallel and placebo controlled
trial of SSI's adjuvanted chlamydia vaccine CTH522: CTH522-CAF01 (CAF01 is an adjuvant
system) and CTH522-Al(OH)3. The trial will be conducted at Imperial College Research site in
the United Kingdom.
Subjects are randomly assigned to one of the following three treatment groups in a ratio of
3:3:1.
This trial consisted of 10 visits and 5 telephonic interviews
Status | Completed |
Enrollment | 35 |
Est. completion date | July 31, 2017 |
Est. primary completion date | July 31, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Is a healthy female between 18 and 45 years of age on the day of first trial vaccination 2. Has provided signed informed consent 3. Is willing and likely to comply with the trial procedures 4. Is prepared to grant authorised persons access to their medical record 5. Willing to use acceptable contraceptive measures* during the trial (2 weeks before and 2 weeks after the trial) - Heterosexually active female capable of becoming pregnant must (in addition to requiring male partner to use condoms) agree to use hormonal contraception, or to complete abstinence, from at least 2 weeks before the first vaccination until at least 2 weeks after the last. (Note: Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal and intrauterine device or intrauterine hormone releasing system and progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, are not acceptable methods of contraception) Exclusion Criteria: 1. Has confirmed history of Pelvic Inflammatory Disease or significant gynaecological diseases 2. Is positive for C. trachomatis (PCR) 3. Is positive for gonorrhoea (urine), HIV, Hepatitis B/C, syphilis (blood) 4. Has a positive pregnancy test 5. Has a significant active disease - such as cardiac, liver, immunological, neurological, psychiatric; or clinically significant abnormality of haematological or biochemical parameters. 6. Has BMI of 35 kg/m2 or greater 7. Is currently participating in another clinical trial with an investigational or noninvestigational drug or device 8. Has received, or plans to receive, an active immunisation within 14 days of the start of the trial or any of the immunisation visits in this trial 9. Is currently receiving treatment with immunosuppressive agents e.g. oral, inhaled, nasal or injected corticosteroids. (Topical steroids are allowed, unless applied to the IM injection site.) 10. Is using an intrauterine device 11. Has a condition which in the opinion of the investigator is not suitable for participation in the trial 12. Known or confirmed allergy to any of the vaccine constituents - |
Country | Name | City | State |
---|---|---|---|
United Kingdom | NIHR/Wellcome Trust Imperial Clinical Research Facility, Hammersmith Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Statens Serum Institut | Imperial College London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of adverse events/reactions and laboratory safety of adjuvanted chlamydia vaccine | Solicited local injection site reactions (recorded at any visit) after intramuscular (IM) administration (pain, erythema, tenderness, pruritus, warmth, stiffness and swelling) Solicited local reactions (recorded at any visit) after IN administration (discharge, including bleeding, congestion, discomfort, sneezing and cough) Solicited systemic reactions (recorded at any visit) after IM and IN administration (abnormally raised temperature, chills, myalgia, malaise, fatigue, rash, headache, nausea and vomiting, and clinically significant abnormal values among full blood count, liver function test and renal profile results) | Through study completion (Day 0 to Day 168) | |
Secondary | Serum immunoglobulin G antibody responses after vaccination with CTH522 | Percentage of subjects achieving seroconversion for anti-CTH522 immunoglobulin G antibody at any time points after IM vaccination(s) | At Days 0, 28, 112, 126, 140, 154 and 168 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03676816 -
Self Sampling for Rapid Turnaround Testing in the Emergency Department
|
N/A | |
Completed |
NCT00213018 -
Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission
|
Phase 2 | |
Completed |
NCT00827970 -
Randomized Population-Based Study on Chlamydia Trachomatis Screening
|
N/A | |
Completed |
NCT01733069 -
Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System
|
N/A | |
Withdrawn |
NCT01358799 -
Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System
|
N/A | |
Completed |
NCT00978848 -
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing
|
N/A | |
Completed |
NCT02391233 -
Multimedia WORTH With Black Drug-Involved Women on Probation
|
N/A | |
Completed |
NCT00973466 -
Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients
|
N/A | |
Completed |
NCT03071510 -
Evaluation of the Atlas Genetics io® CTNG System
|
||
Recruiting |
NCT04446611 -
Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes
|
N/A | |
Completed |
NCT01329588 -
Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers
|
Phase 4 | |
Not yet recruiting |
NCT06216964 -
Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study
|
N/A | |
Terminated |
NCT02795975 -
Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples
|
N/A | |
Completed |
NCT00207454 -
Optimizing Strategies to Improve STD Partner Services
|
Phase 1 | |
Completed |
NCT00213057 -
Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand
|
Phase 1 | |
Completed |
NCT00177437 -
Home Screening for Chlamydia Surveillance
|
Phase 3 | |
Completed |
NCT01665690 -
Washington State Community Expedited Partner Treatment (EPT) Trial
|
Phase 4 | |
Completed |
NCT02128620 -
A Randomized Online Health Experiment for a Safer Youth Sexual Behaviour
|
N/A | |
Completed |
NCT00618449 -
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
|
Phase 4 | |
Recruiting |
NCT01661985 -
Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced
|
Phase 4 |